血液科学(英文)最新文献_第10页

Erratum: RNA editing enzyme ADAR1 is required for early T cell development. RNA编辑酶ADAR1是早期T细胞发育所必需的

IF 1.5

血液科学(英文) Pub Date : 2022-03-08 eCollection Date: 2021-07-01 DOI: 10.1097/BS9.0000000000000082

引用次数: 0

Higher efficacy of oral etoposide for mobilization of peripheral blood stem cells in patients with multiple myeloma 口服依托泊苷对多发性骨髓瘤患者外周血干细胞动员的更高疗效

血液科学(英文) Pub Date : 2022-02-23 DOI: 10.1097/BS9.0000000000000104

W. Qiang, Hua Jiang, Pei Guo, Jing Lu, Jin Liu, Lu Li, Haiyan He, Xiao Hu, W. Fu, J. Du

{"title":"Higher efficacy of oral etoposide for mobilization of peripheral blood stem cells in patients with multiple myeloma","authors":"W. Qiang, Hua Jiang, Pei Guo, Jing Lu, Jin Liu, Lu Li, Haiyan He, Xiao Hu, W. Fu, J. Du","doi":"10.1097/BS9.0000000000000104","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000104","url":null,"abstract":"Abstract This study compares the efficacy, toxicity, hematopoietic recovery, and cost of stem-cell mobilization using intermediate-dose cyclophosphamide (IDCy) plus granulocyte colony-stimulating factor (G-CSF) compared with etoposide (VP-16) plus pegylated granulocyte colony-stimulating factor (PEG-rhG-CSF) in multiple myeloma (MM) patients. Two hundred forty-four consecutive patients undergoing mobilization with IDCy (3-3.5 g/m2) plus G-CSF (n = 155) were compared with patients receiving VP-16 plus PEG-rhG-CSF (n = 89), including oral etoposide (n = 65) and intravenous etoposide (n = 24). Compared with IDCy, VP-16 use was associated with significantly higher median peak peripheral blood CD34 + cell count (8.20 [range: 1.84-84] × 106/kg vs 4.58 [range: 0.1-27.9] × 106/kg, P = .000), and ideal CD34 + cell yield of more than 6 × 106/kg (56.8% vs 35.1%, P = .001), notably with a higher efficacy in oral VP-16 use compared with IDCy use (CD 34 + cell counts: median peak peripheral blood 5.87 vs 4.58 × 106/kg and ≥6 × 106/kg [48.4% vs 35.1%]). The median number of apheresis courses was reduced from two in the IDCy group to one in the VP-16 group (P = .000). IDCy use was associated with significantly more frequent episodes of neutropenia (70.2% vs 35.2%; P = .000), intravenous antibiotic use (13.2% vs 11.4%; P = .672), and hospitalization (P = .000). The recoveries of neutrophils and platelets after autologous stem-cell transplantation were significantly faster in the VP-16 group compared with the IDCy group (P = .000). Our data indicate robust stem-cell mobilization in MM patients with VP-16 delivered either orally or intravenously. When compared with intravenous VP-16, oral VP-16 mobilization was associated with significantly more convenient, lower average total costs, and especially decreased the risk of hospital visits and exposure.","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46586625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum: Ultrastructural alterations of megakaryocytes in thrombocytopenia: A review of 43 cases. 勘误：血小板减少症中巨核细胞的超微结构改变：43 例病例回顾。

IF 1.5

血液科学(英文) Pub Date : 2022-02-15 eCollection Date: 2022-01-01 DOI: 10.1097/BS9.0000000000000096

引用次数: 0

Integrated genomic analyses identify high-risk factors and actionable targets in T-cell acute lymphoblastic leukemia. 综合基因组分析确定T细胞急性淋巴细胞白血病的高危因素和可操作的靶点

IF 1.5

血液科学(英文) Pub Date : 2022-02-04 eCollection Date: 2022-01-01 DOI: 10.1097/BS9.0000000000000102

Haichuan Zhu, Bingjie Dong, Yingchi Zhang, Mei Wang, Jianan Rao, Bowen Cui, Yu Liu, Qian Jiang, Weitao Wang, Lu Yang, Anqi Yu, Zongru Li, Chao Liu, Leping Zhang, Xiaojun Huang, Xiaofan Zhu, Hong Wu

{"title":"Integrated genomic analyses identify high-risk factors and actionable targets in T-cell acute lymphoblastic leukemia.","authors":"Haichuan Zhu, Bingjie Dong, Yingchi Zhang, Mei Wang, Jianan Rao, Bowen Cui, Yu Liu, Qian Jiang, Weitao Wang, Lu Yang, Anqi Yu, Zongru Li, Chao Liu, Leping Zhang, Xiaojun Huang, Xiaofan Zhu, Hong Wu","doi":"10.1097/BS9.0000000000000102","DOIUrl":"10.1097/BS9.0000000000000102","url":null,"abstract":"T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy often associated with poor outcomes. To identify high-risk factors and potential actionable targets for T-ALL, we perform integrated genomic and transcriptomic analyses on samples from 165 Chinese pediatric and adult T-ALL patients, of whom 85% have outcome information. The genomic mutation landscape of this Chinese cohort is very similar to the Western cohort published previously, except that the rate of NOTCH1 mutations is significant lower in the Chinese T-ALL patients. Among 47 recurrently mutated genes in 7 functional categories, we identify RAS pathway and PTEN mutations as poor survival factors for non-TAL and TAL subtypes, respectively. Mutations in the PI3K pathway are mutually exclusive with mutations in the RAS and NOTCH1 pathways as well as transcription factors. Further analysis demonstrates that approximately 43% of the high-risk patients harbor at least one potential actionable alteration identified in this study, and T-ALLs with RAS pathway mutations are hypersensitive to MEKi in vitro and in vivo. Thus, our integrated genomic analyses not only systematically identify high-risk factors but suggest that these high-risk factors are promising targets for T-ALL therapies.","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2022-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48694676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In memory of Hal E. Broxmeyer, a pluripotent scientist, pioneer, and mentor. 纪念全能科学家、先驱和导师Hal E.Broxmeyer

IF 1.5

血液科学(英文) Pub Date : 2022-01-25 eCollection Date: 2022-01-01 DOI: 10.1097/BS9.0000000000000100

Linzhao Cheng, Bin Guo, Xinxin Huang, Tao Cheng

引用次数: 0

China's top 10 hematological advances in 2021 lists the key developments in hematology in China for that year. 2021年中国血液学十大进展列出了当年中国血液学的关键进展

IF 1.5

血液科学(英文) Pub Date : 2022-01-25 eCollection Date: 2022-01-01 DOI: 10.1097/BS9.0000000000000103

Xiaochen Wang

引用次数: 0

Mature plasmacytoid dendritic cells associated with acute myeloid leukemia show similar genetic mutations and expression profiles to leukemia cells 与急性髓系白血病相关的成熟浆细胞样树突状细胞表现出与白血病细胞相似的基因突变和表达谱

血液科学(英文) Pub Date : 2022-01-01 DOI: 10.1097/BS9.0000000000000097

X. Gong, Chunhong Li, Ying Wang, Q. Rao, Y. Mi, Min Wang, H. Wei, Jianxiang Wang

{"title":"Mature plasmacytoid dendritic cells associated with acute myeloid leukemia show similar genetic mutations and expression profiles to leukemia cells","authors":"X. Gong, Chunhong Li, Ying Wang, Q. Rao, Y. Mi, Min Wang, H. Wei, Jianxiang Wang","doi":"10.1097/BS9.0000000000000097","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000097","url":null,"abstract":"Introduction: Mature plasmacytoid dendritic cells (pDCs) proliferation associated with myeloid neoplasms (MPDMN) are recognized as a neoplasm related to fully differentiated pDCs. Although it has been reported for many years, the genomic landscape of MPDMN is poorly understood. Methods: We reported two patients who developed acute myeloid leukemia (French-American-British M5 subtype) coexisted with immunophenotypically mature pDCs proliferation, which fit the diagnosis of MPDMN. We sorted pDCs from myeloid blasts by flow cytometry and performed whole-exome sequencing and RNA sequencing of the two cell populations, respectively. Results: The immunophenotypes of pDCs in both patients were positive for CD123bri, HLA-DR, CD4, CD303, CD304, and negative for CD56, CD34, CD117, and TdT. The variant allele frequency of gene mutations in myeloid blasts and pDCs were similar. The expression data showed myeloid blasts clustered tightly with hematopoietic stem cells, and pDCs from patients clustered tightly with granulocyte-monocyte progenitors/common myeloid progenitor, rather than with pDCs from the GEO platform. Conclusion: Our study suggested that pDCs derived from the leukemic clone, evidenced by a shared mutation profile and similar transcriptional signatures between pDCs and concurrent myeloid blasts.","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46428166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

The impact of venetoclax based regimens in the preemptive of measurable residual disease in acute myeloid leukemia venetoclax为基础的方案在急性髓性白血病可测量残余疾病预防中的影响

血液科学(英文) Pub Date : 2022-01-01 DOI: 10.1097/BS9.0000000000000101

Q. Fang, X. Gong, Yan Li, B. Gong, Yuntao Liu, Kaiqi Liu, Guangji Zhang, Shu-ning Wei, D. Lin, Bing-cheng Liu, Ying Wang, H. Wei, Y. Mi, Jianxiang Wang

{"title":"The impact of venetoclax based regimens in the preemptive of measurable residual disease in acute myeloid leukemia","authors":"Q. Fang, X. Gong, Yan Li, B. Gong, Yuntao Liu, Kaiqi Liu, Guangji Zhang, Shu-ning Wei, D. Lin, Bing-cheng Liu, Ying Wang, H. Wei, Y. Mi, Jianxiang Wang","doi":"10.1097/BS9.0000000000000101","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000101","url":null,"abstract":"To The Editor: The role of measurable residual disease (MRD) in prognosis and treatment in acute myeloid leukemia (AML) is evolving. Studies have demonstrated the correlation between MRD and risks of relapse in adult AML: persistently positive MRD after induction is associated with a high risk of relapse, and these patients should consider allogeneic transplantation (allo-Hematopoietic StemCell Transplantation (HSCT)) and clinical trial, even in favorable-risk groups. However, because of the financial issue or lack of suitable transplant donors, many of the patients could not receive allo-HSCT, so how to prolong the relapse-free survival of these patients remains a challenge. Platzbecker et al treated MRD-positive patients with azacytidine (AZA), and found pre-emptive therapy with AZA can prevent or substantially delay hematological relapse in MRD-positive patients with MDS (myelodysplastic syndrome) or AML who are at a high risk of relapse. What’s more, the application of venetoclax has markedly altered the treatment landscape in AML and provided new opportunities, and preclinical studies have indicated that venetoclax could enhance the activity of anti-leukemic drugs such as HMA (hypomethylating agents), cytarabine, and idarubicin. Moreover, venetoclax with AZA has superior efficacy compared to AZA alone in the treatment of elderly unfit AML patients. Moreover, MRD negative rate after the induction therapy of venetoclax with HMA is much higher (54%–81%) than traditional chemotherapies. Hence, we consider that venetoclax-based regimens could be an efficacious pre-emptive option in patients with persistent MRD positive after induction","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43844304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Advances in measuring DNA methylation DNA甲基化检测进展

血液科学(英文) Pub Date : 2021-12-06 DOI: 10.1097/BS9.0000000000000098

Ruixia Sun, Ping Zhu

引用次数: 5

The novel SLC40A1 (T419I) variant results in a loss-of-function phenotype and may provide insights into the mechanism of large granular lymphocytic leukemia and pure red cell aplasia 新的SLC40A1（T419I）变体导致功能丧失表型，并可能为大颗粒淋巴细胞白血病和纯红细胞再生障碍的机制提供见解

血液科学(英文) Pub Date : 2021-12-06 DOI: 10.1097/BS9.0000000000000099

Hongfei Wu, Xiang Ren, M. Ge, Peiyuan Dong, Shichong Wang, Hui-ming Yi, Xingxin Li, J. Huo, Xuan Zheng, Mengying Gao, Jin-bo Huang, Jing Zhang, Min Wang, P. Jin, N. Nie, Y. Shao, Yizhou Zheng

{"title":"The novel SLC40A1 (T419I) variant results in a loss-of-function phenotype and may provide insights into the mechanism of large granular lymphocytic leukemia and pure red cell aplasia","authors":"Hongfei Wu, Xiang Ren, M. Ge, Peiyuan Dong, Shichong Wang, Hui-ming Yi, Xingxin Li, J. Huo, Xuan Zheng, Mengying Gao, Jin-bo Huang, Jing Zhang, Min Wang, P. Jin, N. Nie, Y. Shao, Yizhou Zheng","doi":"10.1097/BS9.0000000000000099","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000099","url":null,"abstract":"Abstract Variants in the solute carrier family 40 member 1 (SLC40A1) gene are the molecular basis of ferroportin disease, which is an autosomal dominant hereditary hemochromatosis. Here, we present a patient with pure red cell aplasia (PRCA) and large granular lymphocytic leukemia (LGLL) associated with an extremely high levels of serum ferritin and iron overload syndrome. Whole exon sequencing revealed a novel heterozygous variant in SLC40A1 (p.T419I), which was found in his daughter as well. A series of functional studies in vitro of the T419I variant in ferroportin were conducted and the results revealed a reduced capacity of iron export from cells without changes in protein localization and its sensitivity to hepcidin. Intracellular iron storage in mutated cells was significantly higher than that of wild-type. These findings suggest that the novel variant p.T419I can cause the classical form of ferroportin disease and an elevated intracellular iron level indicates a potential novel pathogenic mechanism underlying PRCA and LGLL.","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45910598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0